Ep-CAM(上皮特異抗原)

廣州健侖生物科技有限公司

MOC抗體是一組可以與不同肺癌相關抗原同位素反應的抗體,。它們可以分為兩組,，*組包括 MOC-1, MOC-21, MOC-32 和MOC-52,。它們會優(yōu)先與肺小細胞（SCLC）和良性腫瘤反應,。據(jù)報道，它們能夠檢測冷凍組織切片,。第二組是 MOC31,。它能夠與各種各樣的肺癌反應，包括SCLC,。但它在正常的和惡性的間皮細胞不表達,，可用于腺癌與間皮瘤的研究。干細胞可以轉變?yōu)槿魏晤愋偷募毎?，科學家們一直渴望把這種“超能力”利用起來,。不過，這種“超能力”在癌癥治療中又是一個令人擔憂的問題,。人們認為,，惡性腫瘤中的干細胞能幫助癌癥抵抗治療。zui近一項新研究表明,，癌癥干細胞的威脅超乎人們的想象,。
在此之前，人們只在快速生長的侵襲性腫瘤中鑒定到干細胞,。但華盛頓大學的研究團隊在小鼠模型中發(fā)現(xiàn),，緩慢生長的腫瘤也擁有令人頭疼的干細胞。而且這些低級別癌癥干細胞對抗癌藥物很不敏感,，這項研究發(fā)表在三月十二日的Cell Reports雜志上。

我司還提供其它進口或國產試劑盒：登革熱,、瘧疾,、流感、A鏈球菌,、合胞病毒,、腮病毒、乙腦,、寨卡,、黃熱病、基孔肯雅熱,、克錐蟲病,、違禁品濫用、肺炎球菌,、軍團菌,、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清,、德國SiFin診斷血清,、丹麥SSI診斷血清等產品,。

歡迎咨詢

歡迎咨詢

Ep-CAM(上皮特異抗原)

【產品介紹】

細胞定位：細胞漿/細胞膜

克隆號：MOC-31

同型：IgG1/K

適用組織：石蠟/冰凍

陽性對照：直腸癌/肺腺癌

抗原修復：熱修復（EDTA）

抗體孵育時間：30-60min

Ep-CAM(上皮特異抗原)

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】     歐

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-103室

MOC antibodies are a group of antibodies that react isotopely with different lung cancer-associated antigens. They can be divided into two groups, the first including MOC-1, MOC-21, MOC-32 and MOC-52. They preferentially respond to pulmonary small cells (SCLC) and benign tumors. It is reported that they can detect frozen tissue sections. The second group is MOC31. It can react with a wide variety of lung cancers, including SCLC. But it is not expressed in normal and malignant mesothelial cells and can be used in the study of adenocarcinoma and mesothelioma. Stem cells can be transformed into any type of cell, scientists have been eager to use this "super power." However, this "super power" is another worry in cancer treatment. It is believed that stem cells in malignancies can help treat cancer resistance. A recent new study shows that the threat of cancer stem cells beyond the imagination of people.
Previously, stem cells were identified only in rapidly growing aggressive tumors. But a team from the University of Washington found in the mouse model that slow-growing tumors also have troublesome stem cells. And these low-grade cancer stem cells are not sensitive to anticancer drugs, the study was published in the March 12 issue of Cell Reports.